Hamlet BioPharma Website, Blog & Press Pages

Hamlet BioPharma Website, Blog & Press Pages - aVenture Research

Library

hamletbiopharma.comCrawled Oct 29, 2026

6 pages

Antimicrobial peptide therapy for tuberculosis infections/antimicrobial-peptide-therapy-for-tuberculosis-infections
Hamlet BioPharma announces progress in its tuberculosis project, including a defended PhD thesis on antimicrobial peptide therapy.
Colon cancer/colon-cancer
Hamlet Pharma targets colon cancer patients at risk or diagnosed with the disease for BAMLET treatment.
Commercial collaborations/commercial-collaborations
Hamlet Biopharma partners with international advisory firms to strengthen strategic alliances, including a collaboration with Alpha1H, a clinical-stage oncology asset with fast-track designation.
Infections 2023/infections-3-2

6 pages

A new approach to treating bacterial infections without antibiotics – targeting the disease response rather than the bacteria/a-new-approach-to-treating-bacterial-infections-without-antibiotics-targeting-the-disease-response-rather-than-the-bacteria
Scientists collaborating with Hamlet BioPharma present new molecular concepts for treating bacterial infections at the National Infection Biology meeting.
Immunotherapy - a new approach to treating bacterial infections, including antibiotic resistant strains/immunotherapy-a-new-approach-to-treating-bacterial-infections-including-antibiotic-resistant-strains
Hamlet BioPharma reports progress in treating antibiotic-resistant bacteria using a murine model relevant to human disease.
New discoveries in infection biology, highlighting the rich potential of non-antibiotic treatments of infections/new-discoveries-in-infection-biology-highlighting-the-rich-potential-of-non-antibiotic-treatments-of-infections
Hamlet BioPharma publishes new research identifying patient groups for therapies against bacterial infections, developed with Lund University.
Newsletter: Bladder cancer/newsletter-bladder-cancer

6 pages

Hamlet BioPharma holds digital investor meeting/hamlet-biopharma-haller-digitalt-investerarmote
Hamlet BioPharma holds a digital investor meeting via Zoom on October 17, 2023, due to Catharina Svanborg’s absence at Aktiedagen.
Hamlet BioPharma will be presenting at Aktiedagen, Aktiespararna, on Monday, October 9th, in Lund at 12:10 CET/hamlet-hamlet-biopharma-will-be-presenting-at-aktiedagen-aktiespararna-on-monday-october-9th-in-lund-at-1210-cet
Hamlet BioPharma presents its projects and clinical trials at Aktiedagen, Aktiespararna, and introduces its new CEO, Petter Segelman Lindqvist.
Martin Erixon returns as CEO/martin-erixon-aterintrader-som-vd
The board appoints Martin Erixon as acting CEO, replacing Petter Segelman Lindqvist.
Professor Gabriela Godaly will present valuable insights into the pressing global issues of tuberculosis and antibiotic resistance at the 178th Nobel Symposium in Chemistry in Stellenbosch, South Afri/professor-gabriela-godaly-will-present-valuable-insights-into-the-pressing-global-issues-of-tuberculosis-and-antibiotic-resistance-at-the-178th-nobel-symposium-in-chemistry-in-stellenbosch-south-afri
Gabriela Godaly collaborates with Hamlet BioPharma to develop a peptide-based tuberculosis treatment, showing potent effects in animal models.

6 pages

Board & Executive Team/board-executive-team
Catharina Svanborg/team-member/catharina-svanborg
Professor of Clinical Immunology and Chief Physician at Lund University. Member of the Royal Academy of Sciences (1997). Recipients of national and international awards. Founder and chairman of Hamlet BioPharma.
Elisabeth Parker appointed as Business development expert in Hamlet BioPharma and joins the team on March 3rd/elisabeth-parker-appointed-as-business-development-expert-in-hamlet-biopharma-and-joins-the-team-on-march-3rd
Hamlet BioPharma appoints Elisabeth Parker, PhD, to strengthen business development expertise.
Henrik Sundin/team-member/henrik-sundin
Henrik Sundin has experience as a CEO and board member in the financial sector and is an active investor in multiple companies.

2 pages

Patents/our-patents
PATENTS Cancer Indication Patent Group Description Countries Cancer ALL-ALA This case relates to αLactalbumin complexes that have been engineered to optimize production DE, DK, FI, FR, UK, NL, SE, AU, CA, IN, JP, USA Cancer Alpha1 and Alpha2 fragment complexes This case relates to the αLA fragment complexes – comprising the human Alpha1 or Alpha2 […]
The History of HAMLET/the-history-of-hamlet

1 page

Contact us/contact
For inquiries or further information about HAMLET Pharma, please contact: info@hamletpharma.com, for media & press inquiries, please contact: info@issa-pr.com

1 page